Orchestra BioMed (OBIO) received approval from the US Food and Drug Administration to initiate an updated clinical trial for its Virtue Sirolimus AngioInfusion Balloon, a drug-delivery device for heart patients.
The trial will compare Virtue SAB to Boston Scientific's (BSX) AGENT, a paclitaxel-coated balloon, in the treatment of coronary in-stent restenosis, a condition where arteries narrow again after stent placement, the company said.
Virtue SAB uses a non-coated, microporous balloon technology to deliver liquid sirolimus, ensuring protected delivery and extended release of the drug during the critical 30-day healing period.
The new 12-month trial, expected to start in H2, will enroll 740 patients at up to 75 locations across the US.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。